> Neurogen has paid $3 million as an initial licensing fee for Wyeth's Applindore. Wyeth had been developing Applindore as a treatment for schizophrenia, but Neurogen says it will focus on the drug as a treatment for Parkinson's disease. Report
> Pliva has obtained FDA approval to market a generic version of BMS' cholesterol drug Pravachol. Report
> Phytomedics has announced positive results for a phase II clinical trial of PMI-001 in patients with either new onset or therapy-resistant rheumatoid arthritis. Release
> FDA staffers have raised questions about design limitations that they say may influence the effectiveness of Celebrex in children. An FDA advisory committee will meet tomorrow to consider approving Celebrex for children as young as 2. Report
> Angiotech Pharmaceuticals plans to sell $325 million in senior notes. Report
And Finally... An epidemic of asthma has stumped experts on the possible cause. Article